Acta Neuropathologica

, 116:37

Characterization of antibodies that selectively detect α-synuclein in pathological inclusions

  • Elisa A. Waxman
  • John E. Duda
  • Benoit I. Giasson
Original Paper

DOI: 10.1007/s00401-008-0375-1

Cite this article as:
Waxman, E.A., Duda, J.E. & Giasson, B.I. Acta Neuropathol (2008) 116: 37. doi:10.1007/s00401-008-0375-1


Sensitive detection of α-synuclein (α-syn) pathology is important in the diagnosis of disorders like Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy and in providing better insights into the etiology of these diseases. Several monoclonal antibodies that selectively react with aggregated α-syn in pathological inclusions and reveal extensive and underappreciated α-syn pathology in the brains of diseased patients were previously reported by Duda et al. (Ann Neurol 52:205–210, 2002). We sought to characterize the specificity of some of these antibodies (Syn 505, Syn 506 and Syn 514); using C-terminal and N-terminal truncations of α-syn, all three antibodies were determined to require N-terminal epitopes that minimally comprise amino acids 2–4, but possibly extend to amino acid 12 of α-syn. The selectivity of these antibodies was further assessed using biochemical analysis of human brains and reactivity to altered recombinant α-syn proteins with duplication variants of amino acids 1–12. In addition, by expressing wild-type or a double mutant (E46K/A53T) of α-syn in cultured cells and by comparing their immunoreactivities to another antibody (SNL-4), which has a similar primary epitope, it was determined that Syn 505, Syn 506 and Syn 514 recognize conformational variants of α-syn that is enhanced by the presence of the double mutations. These studies indicate that antibodies Syn 505, Syn 506 and Syn 514 preferentially recognize N-terminal epitopes in complex conformations, consistent with the dramatic conformational change associated with the polymerization of α-synuclein into amyloid fibrils that form pathological inclusions.


α-Synuclein Antibodies Fibrillization Lewy bodies Parkinson’s disease 

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Elisa A. Waxman
    • 1
  • John E. Duda
    • 2
    • 3
  • Benoit I. Giasson
    • 1
  1. 1.Department of PharmacologyUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  2. 2.Department of NeurologyUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  3. 3.Parkinson’s Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical CenterPhiladelphiaUSA